From $14 to $65: The Catch Nobody's Telling You About This Breakout

Hey {{first_name|there}} 👋 — here's your high-conviction breakdown for October 16.

If you have paid time left on an individual Granola plan, we'll match it with a Wispr Flow subscription that includes Notetaker and dictation, and add bonus time, up to 12 months total. Sign in or create a Wispr account and submit proof of your plan to check eligibility.

Try Notetaker Free

The Street acknowledges a real turnaround — but the stock has outrun it. After a ~4x move, analysts are now behind the price: consensus is Hold (3 Buy / 5 Hold), average target $54 vs. $64.69 today — about 16% below the current price. Targets have been rising (BTIG to $74; Craig Hallum upgraded to Buy at $64; Canaccord initiated at $65), yet the average still sits under the stock.

Reality check on the original draft: it claimed “Consensus Buy, 4 Strong Buys, $51.50 target, 25–65% upside.” The stock was ~$42 when that was written. At $64.69 today, consensus is Hold, the average target is $54, and that's roughly 16% downside, not upside.

CareDx is a precision-medicine company built on non-invasive transplant diagnostics. Its donor-derived cell-free DNA (dd-cfDNA) tests detect organ-transplant rejection without painful tissue biopsies, and the model is sticky — clinical testing plus digital patient-management software embedded in transplant-center workflows. It's a ~$3.35B company, and the stock has run from a $14 low to $64.69, near its 52-week high of $72.51.

Correction worth noting: CareDx sold its Lab Products business this year — the Q2 GAAP net income ($110.6M) was inflated by a one-time $113M gain from that sale; non-GAAP net income was $20.0M. And the honest nuance on the 52% growth: volume rose only 17% — the rest came from better reimbursement/ASP and out-of-period (catch-up) collections that don't fully repeat.

CareDx operates almost entirely within US hospital and transplant systems, so direct tariff/supply-chain exposure is low. The dominant force is Medicare reimbursement — the same lever that drove the surge is the key risk.

Teams like Parallel, Turbopuffer, and Wordsmith are already setting the pace on Attio. Get an always-on revenue engine, with agents and workflows that build pipeline, chase every buying signal, and move deals forward with your team. Whether you're working in your browser, inbox, or favorite agent, connect to your customer data in real-time through Attio's web app, MCP, API, and SDK.

Try Attio now

Q2 2026 (reported July 30) was a genuine blowout:

⏰ Timing flag: Q3 2026 results are estimated for ~Nov 3 (~3 weeks out). With the stock above the average target and part of the Q2 beat driven by one-time collections, the bar is high — a clean beat-and-raise justifies the re-rating; any reimbursement wobble could hit a stock that's already run 4x.

Insider activity is mostly routine tax-withholding around vesting; the company itself bought back ~$12.2M of stock earlier in the year (around ~$21) — smart capital allocation before the run, but no notable insider buying up here. Institutions hold a large majority of the float with strong net inflows over the past year (growth and healthcare funds among holders) — a real base, though “over 100% of float” figures reflect short-lending mechanics, not literal ownership.

Negligible — no notable block trades. This is a clinical-data-and-reimbursement story, not a policy trade.

This is where the original draft was most out of date — it described CDNA at ~$42 with resistance in the $44–$55 zone. The stock has blown through all of that and trades near $64.69, just under its 52-week high of $72.51, after running up from a $14 low. It's extended, not basing.

Setup: This is a momentum name at the top of its range, not a pullback bargain. Chasing a 4x move into earnings is high-risk; a disciplined trader waits for either a real pullback toward $54–$58 (back to where analysts value it) or a confirmed post-earnings continuation. Respect the ~Nov 3 catalyst — the gap can go either way, and there's a lot of profit sitting in this chart.

CareDx is a real turnaround — profitable at last, high-margin, debt-free, with a credible oncology growth lever. But the honest framing is the opposite of a “25–65% upside” call: the stock has already 4x'd off its lows, sits near all-time highs, and trades above Wall Street's average target with a Hold consensus. The business deserves credit; the price has already taken most of it. This is a “respect the run, wait for your spot” name — not a fresh breakout to chase, especially three weeks before an earnings report where part of the prior quarter's surge came from collections that won't repeat. If you want exposure, let it come back toward where the Street values it, and size for the volatility.